A longitudinal observational study assessing biologic disease-modifying antirheumatic drug (bDMARD) treatment pathways using sankey diagrams and predictive analysis
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Jan 2022 New trial record
- 09 Nov 2021 Results presented at the ACR Convergence 2021